18 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 18 of 18 clinical reviews.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity: mechanisms, evidence, combination rationale, and safety risks. prepared by the HealthRX.com Editorial Team.
A head-to-head clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) versus compounded low-dose naltrexone for long-term durability, covering trial data, mechanism, dose, and which patients are likely to respond best over time.
A detailed clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN), covering mechanism, trial data, real-world outcomes, and how to choose between them for longevity and immune support.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone across special populations including older adults, autoimmune patients, cancer survivors, and metabolic disease, with dosing, evidence grades, and switching criteria.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone titration protocols, side-effect profiles, and tolerability data to help patients and prescribers choose the right longevity intervention.
A clinical comparison of NMN/NR (nicotinamide mononucleotide/riboside) and low-dose naltrexone (LDN) for longevity and immune modulation, including what the evidence says about switching when one stops working.
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity, including the mechanistic rationale for combining them, real trial data, dosing, and a frank look at risks.
A direct clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for long-term durability of effect, covering trial evidence, mechanisms, switching criteria, and dosing in longevity and immune contexts.
A clinician-reviewed comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity and immune modulation, drawing on real-world evidence, named trials, and dosing data.
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) in special populations, elderly, autoimmune, cancer, metabolic, and immunocompromised patients, with trial data, dosing tables, and switching guidance.
A head-to-head clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) titration protocols, tolerability profiles, and longevity-medicine use cases, with primary-source citations throughout.
A head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, covering mechanisms, trial data, real-world evidence, side-effect profiles, and how to choose between them.
A clinician-reviewed comparison of rapamycin (sirolimus) versus NMN/NR (nicotinamide mononucleotide/riboside) for longevity across special populations including older adults, diabetics, cancer survivors, women on HRT, and immunocompromised patients. Includes trial data, dosing guidance, and switching criteria.
A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including how to recognize failure and when to switch or combine.
A head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for long-term longevity durability, covering mechanism, trial data, and switching decisions.
A head-to-head clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) titration protocols, side-effect profiles, and tolerability data to help you and your clinician choose the right longevity regimen.
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) for longevity and immune modulation, including what evidence supports switching when one drug stops working.
A clinical comparison of rapamycin (sirolimus) and NMN/NR (nicotinamide mononucleotide/riboside) for longevity, including mechanism differences, trial data, combination rationale, and real risks.